ABSTRACT

Introduction

Onychomycosis, a common nail disorder caused by fungal infection, can be managed pharmaceutically with oral or topical treatments. While oral treatments are often used first-line to treat nail infections, these systemic antifungals are not appropriate for all patients, and no oral treatments are approved for use in children in the USA. Given this need, topical antifungals were developed, which can be used as monotherapy or in combination with oral drugs.

Areas Covered

Efinaconazole 10% solution is an azole antifungal indicated for topical treatment of toenail onychomycosis in pediatric and adult patients. This qualitative literature review summarizes available chemical, pharmacological, efficacy, safety, and post-marketing surveillance data of efinaconazole 10% topical solution. Efinaconazole 10% has been shown to be safe and efficacious regardless of disease severity/duration at baseline; patient gender, ethnicity, or age (including pediatrics); or comorbidities such as diabetes or tinea pedis. Overall, efinaconazole is a safe and effective clinical option for the treatment and management of onychomycosis.

Expert Opinion

Efinaconazole is the first new antifungal approved for onychomycosis in 10 years in the USA. It has comparable efficacy to systemic antifungal agents such as itraconazole, and a favorable adverse events profile with minimal systemic exposure and no drug-drug interactions.

中文翻译：

---

艾非康唑局部溶液（10%）用于治疗成人和儿童甲癣

摘要

介绍

甲癣是一种由真菌感染引起的常见指甲疾病，可以通过口服或局部治疗进行药物治疗。虽然口服治疗通常用于治疗指甲感染的一线治疗，但这些全身性抗真菌药并不适合所有患者，并且在美国没有批准用于儿童的口服治疗。鉴于这种需要，开发了局部抗真菌剂，可用作单一疗法或与口服药物联合使用。

涵盖的领域

Efinaconazole 10% 溶液是一种唑类抗真菌剂，适用于局部治疗儿童和成人患者的趾甲真菌病。这篇定性文献综述总结了 10% efinaconazole 局部溶液的可用化学、药理学、功效、安全性和上市后监测数据。无论基线时疾病的严重程度/持续时间如何，10% 的艾非康唑已被证明是安全和有效的；患者性别、种族或年龄（包括儿科）；或合并症，如糖尿病或足癣。总体而言，依氟康唑是治疗和管理甲癣的安全有效的临床选择。

专家意见

Efinaconazole 是 10 年来美国第一个获批用于治疗甲癣的新型抗真菌药物。它具有与伊曲康唑等全身性抗真菌药相当的功效，并且具有良好的不良事件特征，全身暴露最小且没有药物-药物相互作用。